Emerging Immunotherapy Approaches in 1st Line Maintenance Therapy for Advanced UC
Objectives:
- Differentiate the clinical trial design of 1L UC studies
- Review efficacy and safety outcomes of 1L UC trial results reported in 2020
- Discuss factors involved in implementing 1L maintenance for UC patients
Speakers:
Srikala Sridhar MD, MSc, FRCPC
Medical Oncologist, Princess Margaret Cancer Center
Associate Professor, University of Toronto
Chair, GU Medical Oncologists of Canada
Nimira Alimohamed MD, FRCPC
Program Director, Medical Oncology Residency Training Program
Clinical Associate Professor, University of Calgary Chair, Southern Alberta GU Tumour Group Staff
Medical Oncologist, Tom Baker Cancer Centre
√ Accreditation: Section 1 Group Learning
**This webinar is reserved for healthcare professionals and sponsoring companies. Registration will be vetted before event links are provided to participants.
Sponsor: EMD Serono Pfizer